ZA200004313B - Formulation of fast-dissolving efa virenz capsules or tablets using super-disintegrants. - Google Patents

Formulation of fast-dissolving efa virenz capsules or tablets using super-disintegrants.

Info

Publication number
ZA200004313B
ZA200004313B ZA200004313A ZA200004313A ZA200004313B ZA 200004313 B ZA200004313 B ZA 200004313B ZA 200004313 A ZA200004313 A ZA 200004313A ZA 200004313 A ZA200004313 A ZA 200004313A ZA 200004313 B ZA200004313 B ZA 200004313B
Authority
ZA
South Africa
Prior art keywords
virenz
efa
disintegrants
capsules
tablets
Prior art date
Application number
ZA200004313A
Other languages
English (en)
Inventor
William T Makooi-Morehead
John D Buehler
Brian R Landmann
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22160544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200004313(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of ZA200004313B publication Critical patent/ZA200004313B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200004313A 1998-04-07 2000-08-22 Formulation of fast-dissolving efa virenz capsules or tablets using super-disintegrants. ZA200004313B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8092598P 1998-04-07 1998-04-07

Publications (1)

Publication Number Publication Date
ZA200004313B true ZA200004313B (en) 2002-01-30

Family

ID=22160544

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200004313A ZA200004313B (en) 1998-04-07 2000-08-22 Formulation of fast-dissolving efa virenz capsules or tablets using super-disintegrants.

Country Status (27)

Country Link
US (2) US6238695B1 (xx)
EP (1) EP1067936B1 (xx)
JP (1) JP2002510634A (xx)
KR (1) KR100634253B1 (xx)
CN (1) CN1146419C (xx)
AR (1) AR019031A1 (xx)
AT (1) ATE223719T1 (xx)
AU (1) AU756422B2 (xx)
BR (1) BR9908810A (xx)
CA (1) CA2321523C (xx)
CZ (1) CZ300850B6 (xx)
DE (1) DE69902893T2 (xx)
DK (1) DK1067936T3 (xx)
EA (1) EA003217B1 (xx)
EE (1) EE04391B1 (xx)
ES (1) ES2181417T3 (xx)
HU (1) HU228498B1 (xx)
IL (1) IL138078A (xx)
NO (1) NO325824B1 (xx)
NZ (1) NZ507566A (xx)
PL (1) PL194309B1 (xx)
PT (1) PT1067936E (xx)
SK (1) SK284655B6 (xx)
TW (1) TW576741B (xx)
UA (1) UA72207C2 (xx)
WO (1) WO1999051239A1 (xx)
ZA (1) ZA200004313B (xx)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
ES2277682T3 (es) * 1998-06-11 2007-07-16 PHARMACIA & UPJOHN COMPANY LLC Formulacion de delavirdina en comprimido.
US7037524B2 (en) * 2001-10-03 2006-05-02 Herbalscience, Llc Oral delivery of a botanical
US20050069596A1 (en) * 2001-10-03 2005-03-31 Gow Robert T. Compositions and methods comprising kava and anti-anxiety compounds
US20050053678A1 (en) * 2001-10-03 2005-03-10 Gow Robert T. Methods and compositions for betel nut chewing gum
US7291352B2 (en) 2001-10-03 2007-11-06 Herbalscience Llc Methods and compositions for oral delivery of Areca and mate' or theobromine
AU2002359518A1 (en) * 2001-11-27 2003-06-10 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20050037025A1 (en) * 2002-10-03 2005-02-17 Gow Robert T. Methods and compositions comprising kava and mate' or theobromine
DK1583542T3 (da) * 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
WO2006020962A2 (en) 2004-08-13 2006-02-23 Gallipot, Inc. Palatable suspending vehicle for pharmaceutical ingredients
US20060099253A1 (en) * 2004-10-20 2006-05-11 Wyeth Antibiotic product formulation
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
EP1909762A2 (en) * 2005-07-28 2008-04-16 Isp Investments Inc. Amorphous efavirenz and the production thereof
WO2007013047A2 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions
RU2008128424A (ru) * 2005-12-14 2010-01-20 Сипла Лимитед (In) Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы
US20080014228A1 (en) * 2006-07-14 2008-01-17 Olivia Darmuzey Solid form
MX2009002873A (es) * 2006-09-14 2009-05-19 Chemlink Lab Llc Metodo para preparar formas de dosis solida que forman una pasta, crema o gel cuando se diluyen para uso final.
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) * 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
US10189957B2 (en) * 2007-01-26 2019-01-29 Isp Investments Llc Formulation process method to produce spray dried products
US20080181961A1 (en) * 2007-01-26 2008-07-31 Isp Investments, Inc. Amorphous oxcarbazepine and the production thereof
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
CA2697150A1 (en) * 2007-08-17 2009-02-26 Teva Pharmaceutical Industries Ltd. Methods and compositions for controlling the bioavailability of poorly soluble drugs
WO2010008719A2 (en) * 2008-06-16 2010-01-21 Schering Corporation Oral pharmaceutical formulations of vla-4 antagonists
WO2010125572A1 (en) * 2009-04-29 2010-11-04 Hetero Research Foundation Compressed tablets and capsules containing efavirenz
KR101883750B1 (ko) 2010-01-27 2018-07-31 비이브 헬쓰케어 컴퍼니 항바이러스 치료
AU2011244783B2 (en) * 2010-04-20 2015-11-12 Cipla Limited Pharmaceutical compositions
US20130115237A1 (en) 2010-06-09 2013-05-09 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects to augment antiretroviral treatment
CN102872019A (zh) * 2012-09-17 2013-01-16 北京阜康仁生物制药科技有限公司 一种采用微粉化技术的依非韦伦制剂
WO2015059466A1 (en) 2013-10-25 2015-04-30 Cipla Limited Pharmaceutical compositions comprising efavirenz
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
WO2017029226A1 (en) 2015-08-14 2017-02-23 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
CN114404377B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种阿巴卡韦、拉米夫定、依非韦伦复方片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0301006B1 (en) 1986-04-01 1992-05-06 The Upjohn Company Methylprednisolone/sodium carboxymethyl starch tablet composition
IE69269B1 (en) * 1989-04-28 1996-08-21 Daiichi Seiyaku Co Use of fluorine containing pyridone carboxylic acid derivatives for preparing a medicament for the treatment of HIV infections
DK0577913T3 (da) * 1992-07-08 1998-01-26 Santen Oy Ophthalmisk præparat indeholdende timolol-hemihydrat
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
AU1694295A (en) * 1994-01-28 1995-08-15 Merck & Co., Inc. Benzoxazinones as inhibitors of hiv reverse transcriptase
US5663467A (en) * 1995-01-23 1997-09-02 Merck & Co., Inc. Synthesis of cyclopropylacetylene
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
CO5070643A1 (es) 1998-05-27 2001-08-28 Merck & Co Inc Formulacion en tabletas comprimidas

Also Published As

Publication number Publication date
TW576741B (en) 2004-02-21
NO325824B1 (no) 2008-07-21
US20010012518A1 (en) 2001-08-09
US6238695B1 (en) 2001-05-29
WO1999051239A1 (en) 1999-10-14
NO20005043L (no) 2000-10-06
NO20005043D0 (no) 2000-10-06
IL138078A (en) 2005-12-18
ES2181417T3 (es) 2003-02-16
HUP0101517A2 (hu) 2001-11-28
NZ507566A (en) 2002-11-26
EE200000589A (et) 2002-04-15
AU3463799A (en) 1999-10-25
DE69902893D1 (de) 2002-10-17
AU756422B2 (en) 2003-01-09
EP1067936B1 (en) 2002-09-11
DK1067936T3 (da) 2003-02-17
PL194309B1 (pl) 2007-05-31
CN1296412A (zh) 2001-05-23
CZ300850B6 (cs) 2009-08-26
HU228498B1 (en) 2013-03-28
UA72207C2 (uk) 2005-02-15
EA003217B1 (ru) 2003-02-27
ATE223719T1 (de) 2002-09-15
AR019031A1 (es) 2001-12-26
EP1067936A1 (en) 2001-01-17
JP2002510634A (ja) 2002-04-09
SK284655B6 (sk) 2005-08-04
HUP0101517A3 (en) 2002-11-28
CA2321523A1 (en) 1999-10-14
US6555133B2 (en) 2003-04-29
KR20010042473A (ko) 2001-05-25
SK14612000A3 (sk) 2001-07-10
EE04391B1 (et) 2004-12-15
KR100634253B1 (ko) 2006-10-16
IL138078A0 (en) 2001-10-31
CZ20003571A3 (cs) 2001-01-17
BR9908810A (pt) 2000-12-19
CA2321523C (en) 2008-10-07
CN1146419C (zh) 2004-04-21
EA200001030A1 (ru) 2001-04-23
PL343421A1 (en) 2001-08-13
PT1067936E (pt) 2002-12-31
DE69902893T2 (de) 2003-04-30

Similar Documents

Publication Publication Date Title
ZA200004313B (en) Formulation of fast-dissolving efa virenz capsules or tablets using super-disintegrants.
HK1034455A1 (en) Oral pharmaceutical extended release dosage form.
HK1041224A1 (zh) 新的藥物製劑
HUP0204170A3 (en) 5-thia-omega-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient
ZA993338B (en) Pharmaceutical formulations.
IS5541A (is) Áfangatöflur til inntöku
PT1058538E (pt) Comprimidos de desintegracao rapida
ZA987551B (en) Solid pharmaceutical dosage forms
HK1042245A1 (en) Pharmaceutical moxifloxacin preparation.
IL146632A0 (en) Pharmaceutical tablets
HK1040488A1 (en) Pharmaceutical formulations.
GB9818927D0 (en) Pharmaceutical formulation
GB9909154D0 (en) Pharmaceutical formulation
GB9822333D0 (en) Pharmaceutical formulation
GB9817470D0 (en) Pharmaceutical formulation
GB9926251D0 (en) Pharmaceutical formulation
HUP0102116A3 (en) Paroxetine ascorbate, process for its preparation and its pharmaceutical use
SI1067936T1 (en) Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
ZA994697B (en) Pharmaceutical formulation.
ZA99918B (en) Pharmaceutical formulation.
GB9811622D0 (en) Drug formulation
CA83558S (en) Pharmaceutical tablet
CA84666S (en) Pharmaceutical tablet
ZA997229B (en) Medicinal formulation.
GB9928489D0 (en) Pharmaceutical formulation